Replies to post #98173 on Biotech Values

[turtlepower]

I'm not sure I understand what you wrote. Hans bishop seemed to imply that provenge cost should be compared to taxotere costs. That doesn''t seem logical since patients are introduced to chemo once the disease progresses are they not? Please correct me if patients are not reintroduced back to chemo. If they are then provenge is an additional cost and thats a FACT not silly.